FMP
Mar 15, 2023 9:39 AM - Davit Kirakosyan(Last modified: Dec 19, 2023 5:49 PM)
Image credit: FMP
89bio, Inc. (NASDAQ:ETNB) shares rose more than 10% since the company’s reported Q4 results on Friday. R&D came in at $19.1 million and SG&A was $6.3 million. Cash and equivalents ended the quarter at $188.2 million. The company reiterated the March timeline for key ph.IIb pegoza NASH data.
Analysts at RBC Capital said they expect similar data to AKRO's FGF21 analog and believe this will lead to a meaningful stock upside. According to the analysts, pivotal studies in SHTG, an underappreciated opportunity with a low-risk path, remain on track and provide a high valuation floor. The analysts continue to see an attractive buying opportunity into the upcoming data.
May 27, 2024 3:30 PM - Rajnish Katharotiya
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...
Jun 10, 2024 3:46 AM - Parth Sanghvi
Understanding the difference between fixed and variable costs is essential for managing a business’s finances. These costs form the foundation of any cost structure and play a critical role in pricing, budgeting, and profit margin analysis. In this guide, we will explore what fixed and variable cost...
Jul 10, 2024 2:34 AM - Parth Sanghvi
Capital budgeting is a critical financial process that companies use to evaluate and select long-term investments or projects. It involves assessing potential expenditures and determining their profitability to ensure that resources are allocated effectively. This comprehensive guide covers essentia...